Promising Mesothelioma Treatment with PORT-7

911 Meso Info

911 Meso Info is a dedicated voice in the fight against mesothelioma, committed to raising awareness, providing reliable information, and empowering individuals affected by this rare disease. With a passion for advocacy, 911 Meso Info delivers insightful resources, up-to-date research, and practical tips to help patients and families navigate their mesothelioma journey. From treatment options and legal guidance to emotional support and prevention strategies, 911 Meso Info is your go-to source for comprehensive mesothelioma knowledge. Connect with us to stay informed and find strength in community. Follow 911 Meso Info for trusted advice and support, and join us in spreading awareness for a brighter tomorrow.

News Summary

Portage Biotech Inc. reveals promising results of PORT-7, a potential treatment for mesothelioma, at the 2025 European Lung Cancer Congress.

Breakthrough in Mesothelioma Treatment: Portage Biotech’s PORT-7 Shows Promise

In an unexpected turn of events at the 2025 European Lung Cancer Congress, Portage Biotech Inc. unveiled promising preclinical findings concerning their novel drug, PORT-7 (TT-4). This selective Adenosine A2B receptor inhibitor has exhibited significant single-agent effectiveness, raising hopes among those affected by mesothelioma, a rare yet aggressive cancer primarily associated with asbestos exposure.

PORT-7’s Impact on Tumor Growth

The preclinical data suggests that when PORT-7 is combined with an anti-PD1 antibody, it achieves an eyewatering more than 90% inhibition of tumor growth in a murine mesothelioma animal model. This is a groundbreaking revelation as it marks the first reported instance of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. The implications of this combination therapy could redefine the way specialists approach treatment for this deadly disease.

Immune Response and Tumor Infiltration

Immunohistochemistry analyses from these studies demonstrated a notable infiltration of immune effector cells, specifically CD3 and CD45 positive cells, within the tumor environment. The significant infiltration suggests that PORT-7 not only targets the tumor but also mobilizes the immune system to combat the cancer more effectively.

Next Steps for Portage Biotech

With these promising results in hand, Portage is set to start a first-in-human clinical trial to further investigate the potential of PORT-7. In tandem, the company is advancing dose escalation studies for PORT-6, another selective inhibitor affecting the A2A adenosine receptor. The dual approach plans to co-administer PORT-6 with PORT-7 in the ongoing ADPORT-601 trial, aiming for a comprehensive blockade of adenosine-induced immunosuppression within the tumor microenvironment.

A New Hope for Patients

This innovative strategy aspires to neutralize the immunosuppressive effects of adenosine completely, enhancing the body’s natural antitumor responses and potentially broadening the impact of immunotherapy for those suffering from solid tumors, including mesothelioma. The results not only present new avenues for therapy but also give a glimmer of hope to patients diagnosed with this aggressive form of cancer.

Market Response and Future Developments

Portage Biotech is experiencing an incredible surge, with its stock soaring 102.93%, reaching $9.60 following the promising news. Although its year-to-date price performance remains at -6.97%, the technical sentiment signal for Portage Biotech is currently rated as a Strong Buy. Analysts and investors alike are eyeing this biotechnology company closely, given its recent developments.

Furthermore, Portage is in discussions with Immunova LLC regarding a potential acquisition of its subsidiary, iOx Therapeutics, Ltd., which focuses on developing liposomal iNKT agonists. The lead candidate, PORT-2, has reportedly shown encouraging early clinical results, adding further intrigue to Portage’s growing pipeline.

Conclusion: A Noteworthy Development in Cancer Treatment

With an array of innovative products in development, Portage Biotech stands at the forefront of potential breakthroughs in cancer treatment, particularly for mesothelioma patients grappling with limited options. The unfolding narrative surrounding PORT-7 and its combination strategies suggests a reimagining of how cancer therapies could turn the tide in favor of patients worldwide. As research progresses, the hope remains that these advancements could lead to meaningful impacts in the fight against one of the most challenging cancers known to humanity.